Prestige Consumer Healthcare (NYSE:PBH) VP Jeffrey Zerillo Sells 1,207 Shares

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jeffrey Zerillo also recently made the following trade(s):

• On Tuesday, May 5th, Jeffrey Zerillo sold 346 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $55.32, for a total value of $19,140.72.
• On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $65.93, for a total value of $65,930.00.

Prestige Consumer Healthcare Stock Up 0.3%

Shares of PBH opened at $54.49 on Friday. The stock has a fifty day simple moving average of $60.23 and a two-hundred day simple moving average of $61.92. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $2.58 billion, a PE ratio of 14.42, a price-to-earnings-growth ratio of 1.62 and a beta of 0.40. Prestige Consumer Healthcare Inc. has a 52-week low of $51.24 and a 52-week high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. During the same period in the prior year, the company posted $1.22 EPS. The company’s revenue for the quarter was down 2.4% compared to the same quarter last year. As a group, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.54 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after acquiring an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after purchasing an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares during the period. Jane Street Group LLC raised its position in Prestige Consumer Healthcare by 204.0% in the first quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after purchasing an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PBH has been the subject of a number of recent analyst reports. Oppenheimer cut their price target on shares of Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a report on Thursday. Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $74.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).